BLA 761040 · Wyeth Pharms INC
Besponsa
Inotuzumab Ozogamicin · CD22-directed Immunoconjugate
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Mar 6, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Aug 17, 2017
Approved uses
2
Original approval plus efficacy supplements
Registered trials
70
9 Phase 3, 21 recruiting
FAERS reports
2,992
2,854 serious, 1,018 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HEPATOTOXICITY, INCLUDING HEPATIC VENO-OCCLUSIVE DISEASE (VOD) (ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME) and INCREASED RISK OF POST-HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) NON-RELAPSE MORTALITY WARNING: HEPATOTOXICITY, INCLUDING HEPATIC VENO-OCCLUSIVE DISEASE (VOD) (ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME) and INCREASED RISK OF POST- HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) NON-RELAPSE MORTALITY See full prescribing information for complete boxed warning. • Hepatotoxicity, including fatal and life-threatening VOD occurred in patients who received BESPONSA. ( 5.1 ) • A higher post-HSCT non-relapse mortality rate occurred in patients receiving BESPONSA ( 5.2 ) HEPATOTOXICITY, INCLUDING VOD • Hepatotoxicity, including fatal and life-threatening VOD occurred in patients with relapsed or refractory acute lymphoblastic leukemia (ALL) who received BESPONSA. The risk of...
What it is approved for
From the label in effect Feb 6, 2026.
1. INDICATIONS AND USAGE BESPONSA is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older . BESPONSA is a CD22-directed antibody and cytotoxic drug conjugate indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older. ( 1 )
Mechanism: Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate (ADC). Inotuzumab recognizes human CD22. The small molecule, N-acetyl-gamma-calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of inotuzumab ozogamicin is due to the binding of the ADC to CD22-expressing tumor cells, followed by internalization of the ADC-CD22 complex, and the intracellular release of N-acetyl-gamma-calicheamicin dimethylhydrazide via hydrolytic cleavage of the linker. Activation of N-acetyl-gamma-calicheamicin...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 6, 2024 Supplement 3 · Efficacy · priority review OrphanLabelLetter
- Aug 17, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- BESPONSA · INOTUZUMAB OZOGAMICIN 0.9/MG/VIAL · POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Inotuzumab Ozogamicin" as an intervention, any sponsor and status, largest first.
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic LeukaemiaPivotal-lookingRecruiting
Mats HeymanAcademic, hospital or other
NCT04307576 · 6,430 participants (planned) · Start Jul 13, 2020 · Primary completion Jun 2033
Drug: Omitted Doxorubicin; Omitted Vincristine+Dexamethasone pulses and 4 more · For: Leukemia, Acute Lymphoblastic
Sites: Brussels, Belgium; Edegem, Belgium; Ghent, Belgium · 137 sites in all
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)Pivotal-lookingRecruiting
Charite University, Berlin, GermanyAcademic, hospital or other
NCT07476729 · 750 participants (planned) · Start Sep 1, 2026 · Primary completion Mar 31, 2033
Drug: Inotuzumab ozogamicin (INO); Blinatumomab · For: B-Cell Acute Lymphoblastic Leukaemia
Sites: Vienna, Austria; Ghent, Belgium; Prague, Czechia · 21 sites in all
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in AdultsPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT04530565 · 348 participants (planned) · Start Jan 25, 2021 · Primary completion Jul 1, 2028
Drug: Blinatumomab; Cyclophosphamide and 9 more · For: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Sites: Birmingham, Alabama; Anchorage, Alaska; Fort Smith, Arkansas · 211 sites in all
- A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose ChemotherapyPivotal-lookingTerminated
PfizerPfizer (PFE)
NCT01232556 · 338 participants · Start Apr 4, 2011 · Primary completion Mar 28, 2014
Drug: Inotuzumab ozogamicin; Rituximab and 2 more · For: Lymphoma, Non-Hodgkin
Sites: Burbank, California; Fresno, California; Los Angeles, California · 177 sites in all
- A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01564784 · 326 participants · Start Aug 2, 2012 · Primary completion Mar 8, 2016
Drug: inotuzumab ozogamicin; FLAG (fludarabine, cytarabine and G-CSF) and 2 more · For: Acute Lymphoblastic Leukemia
Sites: La Jolla, California; Los Angeles, California; Orange, California · 198 sites in all
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaPivotal-lookingRecruiting
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT03150693 · 303 participants (planned) · Start Sep 20, 2017 · Primary completion Nov 1, 2027
Drug: Allopurinol; Cytarabine and 11 more · For: B Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 460 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT01371630 · 276 participants (planned) · Start Aug 26, 2011 · Primary completion Dec 25, 2027
Drug: Blinatumomab; Cyclophosphamide and 8 more · For: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Burkitt-Like Lymphoma With 11q Aberration and 6 more
Sites: Houston, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death360
- febrile neutropenia267
- venoocclusive liver disease260
- off label use232
- pyrexia198
- neoplasm progression155
- thrombocytopenia154
- acute lymphocytic leukaemia recurrent148
- drug ineffective143
- cytokine release syndrome142
- sepsis138
- venoocclusive disease132
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 5 |
| 2009 | 4 |
| 2010 | 13 |
| 2011 | 13 |
| 2012 | 29 |
| 2013 | 29 |
| 2014 | 64 |
| 2015 | 71 |
| 2016 | 78 |
| 2017 | 77 |
| 2018 | 245 |
| 2019 | 251 |
| 2020 | 255 |
| 2021 | 368 |
| 2022 | 365 |
| 2023 | 350 |
| 2024 | 343 |
| 2025 | 254 |
| 2026 | 177 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Besponsa (Inotuzumab Ozogamicin) · HCPCS J9229
2024 spending
$20.7M
Beneficiaries
143
680 claims
Per beneficiary
$144,884
2024 ASP limit $2,599.50 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $23,701,002 |
| 2021 | $16,830,601 |
| 2022 | $16,719,295 |
| 2023 | $19,346,167 |
| 2024 | $20,718,365 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.
Jabbour E, Short NJ, Senapati J, et al. · Lancet Haematol 2023 · Clinical Trial, Phase II
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Kantarjian HM, DeAngelo DJ, Stelljes M, et al. · N Engl J Med 2016 · Clinical Trial, Phase III, Comparative Study
- A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.
Short NJ, Jabbour E, Jain N, et al. · Blood Adv 2024 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Kantarjian HM, DeAngelo DJ, Stelljes M, et al. · Cancer 2019 · Clinical Trial, Phase III, Multicenter Study
- Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
Chevallier P, Leguay T, Delord M, et al. · J Clin Oncol 2024 · Clinical Trial, Phase II, Multicenter Study
- Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
Roddie C, Dias J, O'Reilly MA, et al. · J Clin Oncol 2021 · Clinical Trial, Phase I, Multicenter Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.